KBC Group NV Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT

KBC Group NV bought a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 77,139 shares of the company’s stock, valued at approximately $857,000. KBC Group NV owned approximately 0.10% of Phathom Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Phathom Pharmaceuticals in the fourth quarter valued at $27,000. Kestra Advisory Services LLC acquired a new stake in Phathom Pharmaceuticals in the fourth quarter valued at $38,000. Summit Securities Group LLC bought a new position in shares of Phathom Pharmaceuticals in the 1st quarter valued at about $34,000. Raymond James Financial Inc. bought a new position in shares of Phathom Pharmaceuticals in the 2nd quarter valued at about $30,000. Finally, BNP Paribas Financial Markets grew its position in shares of Phathom Pharmaceuticals by 71.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company’s stock valued at $49,000 after acquiring an additional 2,122 shares during the period. 99.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PHAT has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a report on Wednesday, June 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.50.

Phathom Pharmaceuticals Price Performance

PHAT stock opened at $11.44 on Friday. Phathom Pharmaceuticals, Inc. has a one year low of $8.02 and a one year high of $18.31. The stock has a market cap of $912.45 million, a price-to-earnings ratio of -5.40 and a beta of 0.49. The company has a fifty day moving average price of $10.86 and a two-hundred day moving average price of $11.90.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.